myriad genetics - Search News

Myriad Genetics, Piper Sandler

Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup

Myriad Genetics (NASDAQ:MYGN) traded higher on Wednesday after Piper Sandler upgraded the cancer test developer to Overweight from Neutral and raised its price target by $1.00 to $12.50 per share, indicating a balanced risk-reward setup.

Benzinga · 1d

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Fintel on MSN · 2d

Piper Sandler Upgrades Myriad Genetics (MYGN)

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. Analyst Price Forecast Suggests 84.10% Upside As of March 4,

Markets Insider · 2d

Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more

StockStory.org on MSN · 16d

Why Myriad Genetics (MYGN) Shares Are Plunging Today

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 guidance for both revenue and EBITDA coming in light.

Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Schaeffer's Investment Research2d

Medical Equipment Stock Jumps on Upgrade

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

15d

UBS Group Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...

Yahoo Finance19d

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. Myriad Genetics beat analysts’ revenue expectations ...

CNN10d

Myriad Genetics, Inc.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...

manilatimes17d

Myriad Genetics Announces Senior Leadership Transition

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results